TAFA1/FAM19A1 Antibody [Unconjugated]

TAFA1/FAM19A1 was detected in immersion fixed paraffin-embedded sections of human brain (cortex) using Goat Anti-Human TAFA1/FAM19A1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF5154) at 15 µg/mL overnight at 4 °C. Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS008) and counterstained with hematoxylin (blue). Lower panel shows a lack of labeling when primary antibodies are omitted and tissue is stained only with secondary antibody followed by incubation with detection reagents. View our protocol for Chromogenic IHC Staining of Paraffin-embedded Tissue Sections.

The inhibition of FAM19A1 promotes stemness and proliferation of NSCs. (A) Bright field microscopy of neurospheres in si-FAM19A1 and control group, n = 6, Scale bar = 500 μm. (B) EdU labeling in si-FAM19A1 and control group, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of (A,B). (D) RT-qPCR of FAM19A1 and stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 4. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 4. (F) Corresponding quantifications and statistics of (E). For statistical analysis, *p < 0.05, **p < 0.01, compared with the NC-siRNA group. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

si-FAM19A1 could rescue weakened stemness and proliferation of NSCs caused by miR-582-5p inhibitor. (A) Bright field microscopy of neurospheres in the NC-inhibitor and NC-siRNA co-transfection group, the NC-inhibitor and si-FAM19A1 group, the miR-582-5p inhibitor and NC-siRNA group, and the miR-582-5p inhibitor and si-FAM19A1 group, n = 6, Scale bar = 500 μm. (B) EdU labeling of the four groups, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of A and B. Two-way ANOVA with Dunnett’s test. (D) RT-qPCR of stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 3. Two-way ANOVA with Dunnett’s test. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 5. (F) Corresponding quantifications and statistics of E. Two-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

miR-582-5p down-regulates the expression of FAM19A1. (A) RNA-seq of miR-582-5p mimic and NC-mimic transfected NSCs, n = 3. (B) The mRNA expression of potential target genes in the mimic and NC-mimic group, with FAM19A1 down-regulated, n = 4. (C) RT-qPCR analysis of FAM19A1 in the inhibitor and NC-inhibitor group, n = 7. (D) RT-qPCR analysis of FAM19A1 in the GSI and control DMSO group, n = 6. (E,E’) Western blotting and statistics of FAM19A1 in the mimic/inhibitor and control group, n = 4. (F) The sequence of the FAM19A1 3′UTR and the binding site of miR-582-5p (red font). (G) The relative luciferase activity of the FAM19A1 3′UTR reporter with the increase of miR-582-5p concentration, n = 3. One-way ANOVA with Dunnett’s test. (H) The expression of firefly luciferase mRNA with the increase of miR-582-5p concentration, n = 4. One-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

The inhibition of FAM19A1 promotes stemness and proliferation of NSCs. (A) Bright field microscopy of neurospheres in si-FAM19A1 and control group, n = 6, Scale bar = 500 μm. (B) EdU labeling in si-FAM19A1 and control group, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of (A,B). (D) RT-qPCR of FAM19A1 and stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 4. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 4. (F) Corresponding quantifications and statistics of (E). For statistical analysis, *p < 0.05, **p < 0.01, compared with the NC-siRNA group. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

si-FAM19A1 could rescue weakened stemness and proliferation of NSCs caused by miR-582-5p inhibitor. (A) Bright field microscopy of neurospheres in the NC-inhibitor and NC-siRNA co-transfection group, the NC-inhibitor and si-FAM19A1 group, the miR-582-5p inhibitor and NC-siRNA group, and the miR-582-5p inhibitor and si-FAM19A1 group, n = 6, Scale bar = 500 μm. (B) EdU labeling of the four groups, n = 6, Scale bar = 100, 50 μm. (C) Corresponding quantifications and statistics of A and B. Two-way ANOVA with Dunnett’s test. (D) RT-qPCR of stemness markers Sox2, Nestin, Pax6, CD133, and glast, n = 3. Two-way ANOVA with Dunnett’s test. (E) Western blotting analysis of Sox2, Nestin, and Pax6, n = 5. (F) Corresponding quantifications and statistics of E. Two-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

miR-582-5p down-regulates the expression of FAM19A1. (A) RNA-seq of miR-582-5p mimic and NC-mimic transfected NSCs, n = 3. (B) The mRNA expression of potential target genes in the mimic and NC-mimic group, with FAM19A1 down-regulated, n = 4. (C) RT-qPCR analysis of FAM19A1 in the inhibitor and NC-inhibitor group, n = 7. (D) RT-qPCR analysis of FAM19A1 in the GSI and control DMSO group, n = 6. (E,E’) Western blotting and statistics of FAM19A1 in the mimic/inhibitor and control group, n = 4. (F) The sequence of the FAM19A1 3′UTR and the binding site of miR-582-5p (red font). (G) The relative luciferase activity of the FAM19A1 3′UTR reporter with the increase of miR-582-5p concentration, n = 3. One-way ANOVA with Dunnett’s test. (H) The expression of firefly luciferase mRNA with the increase of miR-582-5p concentration, n = 4. One-way ANOVA with Dunnett’s test. For statistical analysis, *p < 0.05, **p < 0.01, ***p < 0.001, compared with the control, respectively. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/35685988), licensed under a CC-BY license. Not internally tested by R&D Systems.

• Reactivity: Hu
• Applications: WB, IHC, B/N
• Clonality: Polyclonal
• Host: Goat
• Conjugate: Unconjugated
• Concentration: LYOPH

TAFA1/FAM19A1 Antibody [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human TAFA1/FAM19A1
  Ser26-Thr133
  Accession # NP_998774
• Specificity: Detects human TAFA1/FAM19A1 in direct ELISAs and Western blots. In direct ELISAs, approximately 15% cross-reactivity with recombinant human (rh) TAFA3 and rhTAFA4 is observed, less than 10% cross-reactivity with rhTAFA2 is observed and less than 1% cross-reactivity with rhTAFA5 is observed.
• Source: N/A
• Isotype: IgG
• Clonality: Polyclonal
• Host: Goat
• Gene: FAM19A1
• Purity Statement: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • Immunohistochemistry 5-15 ug/mL
  • Neutralization 15 ug/mL
  • Western Blot 0.1 ug/mL

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.
  *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Concentration: LYOPH
• Reconstitution Instructions: Sterile PBS to a final concentration of 0.2 mg/mL. For liquid material, refer to CoA for concentration.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TAFA1/FAM19A1 Antibody [Unconjugated]

• Chemokine-like protein TAFA-1
• FAM19A1
• family with sequence similarity 19 (chemokine (C-C motif)-like), member A1
• TAFA1
• TAFA-1

Background

TAFA1 (also FAM19A1) is a secreted, 13 kDa member of the FAM19/TAFA family of chemokine-like proteins (1). It is synthesized as a 133 amino acid (aa) precursor that contains a 19 aa signal sequence and a 114 aa mature chain. Like other members of the FAM19/TAFA family, mature TAFA1 contains 10 regularly spaced cysteine residues that follow the pattern CX7CCX13CXCX14CX11CX4CX5CX10C, in which C represents a conserved cysteine residue and X represents a noncysteine amino acid (1). Human TAFA1 is 100% aa identical to mouse TAFA1. TAFA1 is expressed exclusively in the brain, with highest expression in the frontal cortex, temporal cortex, occipital cortex, parietal cortex and medulla, and low levels in the basal ganglion, thalamus, and cerebellum (1). The biological functions of TAFA family members remain to be determined, but there are a few tentative hypotheses. First, TAFAs may modulate immune responses in the CNS by functioning as brain-specific chemokines, and may act with other chemokines to optimize the recruitment and activity of immune cells in the CNS (1). Second, TAFAs may represent a novel class of neurokines that act as regulators of immune nervous cells (1, 2). And third, TAFAs may control axonal sprouting following brain injury (1).

1. Tang, Y.T. et al. (2004) Genomics 83:727.
2. Benveniste, E. (1998) Cytokine Growth Factor Rev. 9:259.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Gene Symbol: FAM19A1
• Uniprot:
  • NP_998774()